Sobi
Presence
Investor AB is one of the...
Investor AB is a company listed under the stock ticker INVEb.ST (SE).
Investor AB has a direct presence in 7 countries.Investor AB has 15 subsidiaries including Aequus Pharma, CTI BioPharma and CTI Life Sciences.
They are in:
- Healthcare31%
- Pharmaceuticals25%
- Other44%
Acquisition, funding and merger involving Investor AB.
- Sobi has acquired CTI BioPharma (posted on June 27 2023).
- Sobi has announced the acquisition of CTI BioPharma (posted on May 10 2023).
Executives
View the org chart displaying its 72 main executives
Most searched biographies at Sobi
- Guido Oelkers, President and Chief Executive Officer
- Helena Saxon, Director
- Annette Clancy, Chairman of the Board
Popular executive movements at Sobi
- Zlatko Rihter has joined the company as Director (posted on May 16 2024).
- Bo Jesper Hansen, Chairman of the Board, has left the company (posted on January 5 2024).
- Annette Clancy, who was Director, is promoted to Chairman of the Board (posted on January 5 2024).
Click here to view some more movements at Sobi
Popular executive movements at Investor AB
- Christian Cederholm has joined the company as Director (posted on May 8 2024).
- Katarina Berg has joined the company as Director (posted on May 8 2024).
- Christian Cederholm who is Head Patricia Industries, will be promoted to President and Chief Executive Officer on May 7, 2024 (posted on December 4 2023).
Click here to view some more movements at Investor AB
Create your alert
to follow the executive moves at Sobi.
Pharmaceuticals
Investor AB has 1,859 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Sobi
- Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH
- Press releases
- Sobi has completed SEK 3 billion senior bond issue
- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
- Invitation: Sobi's Q1 2024 report
- Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
- Sobi publishes Annual and sustainability report for 2023
- Press releases
- Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
- View more press releases Close
Social media about Sobi
- Sobi on Wikipedia, Google News & Yahoo Finance
- Sobi on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Guido Oelkers 
